Literature DB >> 1909738

Human endothelial cells are activated by IFN-gamma to inhibit Toxoplasma gondii replication. Inhibition is due to a different mechanism from that existing in mouse macrophages and human fibroblasts.

J P Woodman1, I H Dimier, D T Bout.   

Abstract

Toxoplasma gondii invaded and proliferated in cultured human umbilical vein endothelial cells. Preincubation of the human umbilical vein endothelial cells with human rIFN-gamma induced a high degree of inhibition of T. gondii replication, with the effect being dose dependent. In order to try to elucidate the inhibitory mechanism, we tested the presence of several factors that are known to operate against intracellular parasites in other cell types. We found, by means of a competitive inhibitor, that L-arginine-dependent production of reactive nitrogen intermediates was not the cause of inhibition of T. gondii proliferation, thus contrasting with the inhibitory mechanism found in activated mouse macrophages. Furthermore, the inhibition of replication was not overcome by oxygen scavengers or by saturation of the system with tryptophan, suggesting that neither reactive oxygen intermediates nor the induction of tryptophan starvation was responsible.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909738

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Differential infectivity and division of Toxoplasma gondii in human peripheral blood leukocytes.

Authors:  J Y Channon; R M Seguin; L H Kasper
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

2.  Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase.

Authors:  W Däubener; B Spors; C Hucke; R Adam; M Stins; K S Kim; H Schroten
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

3.  Dendritic cells as effector cells: gamma interferon activation of murine dendritic cells triggers oxygen-dependent inhibition of Toxoplasma gondii replication.

Authors:  F Aline; D Bout; I Dimier-Poisson
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

4.  Cell death of gamma interferon-stimulated human fibroblasts upon Toxoplasma gondii infection induces early parasite egress and limits parasite replication.

Authors:  Wendy Niedelman; Joris K Sprokholt; Barbara Clough; Eva-Maria Frickel; Jeroen P J Saeij
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

Review 5.  Cordelia, Goneril and the febrile response.

Authors:  P A Mackowiak
Journal:  Trans Am Clin Climatol Assoc       Date:  1997

6.  IFN-γ +874 T/A polymorphisms contributes to cervical cancer susceptibility: a meta-analysis.

Authors:  Nannan Liu; Yan Song; Weifeng Shi
Journal:  Int J Clin Exp Med       Date:  2015-03-15

7.  In vitro investigation of host resistance to Toxoplasma gondii infection in microglia of BALB/c and CBA/Ca mice.

Authors:  Y R Freund; N T Zaveri; H S Javitz
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

8.  Inhibition of Legionella pneumophila growth by gamma interferon in permissive A/J mouse macrophages: role of reactive oxygen species, nitric oxide, tryptophan, and iron(III).

Authors:  S J Gebran; Y Yamamoto; C Newton; T W Klein; H Friedman
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Endothelial cells are activated by cytokine treatment to kill an intravascular parasite, Schistosoma mansoni, through the production of nitric oxide.

Authors:  I P Oswald; I Eltoum; T A Wynn; B Schwartz; P Caspar; D Paulin; A Sher; S L James
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

10.  The gamma interferon (IFN-gamma)-inducible GTP-binding protein IGTP is necessary for toxoplasma vacuolar disruption and induces parasite egression in IFN-gamma-stimulated astrocytes.

Authors:  T Melzer; A Duffy; L M Weiss; S K Halonen
Journal:  Infect Immun       Date:  2008-09-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.